{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:42:07Z","timestamp":1791859327417,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Emerging SARS-CoV-2 variants, particularly the Omicron variant and its sublineages, continually threaten the global public health. Small molecule antivirals are an effective treatment strategy to fight against the virus. However, the first-generation antivirals either show limited clinical efficacy and\/or have some defects in pharmacokinetic (PK) properties. Moreover, with increased use of these drugs across the globe, they face great pressure of drug resistance. We herein present the discovery and characterization of a new generation antiviral drug candidate (SY110), which is a potent and selective inhibitor of SARS-CoV-2 main protease (M\n                    <jats:sup>pro<\/jats:sup>\n                    ). This compound displayed potent in vitro antiviral activity against not only the predominant SARS-CoV-2 Omicron sublineage BA.5, but also other highly pathogenic human coronaviruses including SARS-CoV-1 and MERS-CoV. In the Omicron-infected K18-hACE2 mouse model, oral treatment with SY110 significantly lowered the viral burdens in lung and alleviated the virus-induced pathology. Importantly, SY110 possesses favorable PK properties with high oral drug exposure and oral bioavailability, and also an outstanding safety profile. Furthermore, SY110 exhibited sensitivity to several drug-resistance M\n                    <jats:sup>pro<\/jats:sup>\n                    mutations. Collectively, this investigation provides a promising new drug candidate against Omicron and other variants of SARS-CoV-2.\n                  <\/jats:p>","DOI":"10.1038\/s41392-023-01392-w","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T15:55:44Z","timestamp":1679846144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants"],"prefix":"10.1038","volume":"8","author":[{"given":"Chong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-3024","authenticated-orcid":false,"given":"Anjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-7898","authenticated-orcid":false,"given":"Zhen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaemin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxue","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronggang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinshan","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-0554","authenticated-orcid":false,"given":"Jian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-9837","authenticated-orcid":false,"given":"Hin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"1392_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"1392_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.","year":"2020","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536\u2013544 (2020).","journal-title":"Nat. Microbiol."},{"key":"1392_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"1392_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1392_CR5","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e13 (2022).","journal-title":"Cell"},{"key":"1392_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"1392_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1392_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466.e4 (2022).","journal-title":"Cell"},{"key":"1392_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1126\/science.abn7760","volume":"375","author":"D Mannar","year":"2022","unstructured":"Mannar, D. et al. SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 375, 760\u2013764 (2022).","journal-title":"Science"},{"key":"1392_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"1392_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"1392_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.abd7343","volume":"370","author":"CM Saad-Roy","year":"2020","unstructured":"Saad-Roy, C. M. et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science 370, 811\u2013818 (2020).","journal-title":"Science"},{"key":"1392_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"1392_CR14","doi-asserted-by":"publisher","first-page":"100682","DOI":"10.1016\/j.genrep.2020.100682","volume":"19","author":"RA Khailany","year":"2020","unstructured":"Khailany, R. A., Safdar, M. & Ozaslan, M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 19, 100682 (2020).","journal-title":"Gene Rep."},{"key":"1392_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1099\/0022-1317-83-3-595","volume":"83","author":"A Hegyi","year":"2002","unstructured":"Hegyi, A. & Ziebuhr, J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 83, 595\u2013599 (2002).","journal-title":"J. Gen. Virol."},{"key":"1392_CR16","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763\u20131767 (2003).","journal-title":"Science"},{"key":"1392_CR17","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1111\/febs.12936","volume":"281","author":"R Hilgenfeld","year":"2014","unstructured":"Hilgenfeld, R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 281, 4085\u20134096 (2014).","journal-title":"FEBS J."},{"key":"1392_CR18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","volume":"184","author":"L Lu","year":"2021","unstructured":"Lu, L., Su, S., Yang, H. & Jiang, S. Antivirals with common targets against highly pathogenic viruses. Cell 184, 1604\u20131620 (2021).","journal-title":"Cell"},{"key":"1392_CR19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1038\/s41401-021-00851-w","volume":"43","author":"CR Wu","year":"2022","unstructured":"Wu, C. R., Yin, W. C., Jiang, Y. & Xu, H. E. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol. Sin. 43, 3021\u20133033 (2022).","journal-title":"Acta Pharmacol. Sin."},{"key":"1392_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"1392_CR21","unstructured":"US Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment (2022); https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment."},{"key":"1392_CR22","unstructured":"U.S. Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults (2022); https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain."},{"key":"1392_CR23","unstructured":"US Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 (2022); https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19."},{"key":"1392_CR24","unstructured":"Ministry of Health, Labour and Welfare of Japan (MHW): about urgent approval of new-style coronavirus medicine. (2022); https:\/\/www.mhlw.go.jp\/stf\/newpage_29320.html."},{"key":"1392_CR25","unstructured":"China National Medical Products Administration (NMPA): domestically developed drug joins virus battle (2022); http:\/\/english.nmpa.gov.cn\/2022-08\/15\/c_797867.htm."},{"key":"1392_CR26","unstructured":"China National Medical Products Administration (NMPA): NMPA conditionally approved the marketing of the combined packaging of Simnotrelvir Tablets\/Ritonavir Tablets and Renmindevir Hydrobromide Tablets for COVID-19 treatment (2023); https:\/\/www.nmpa.gov.cn\/zhuanti\/yqyjzxd\/yqyjxd\/20230129143814163.html."},{"key":"1392_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273\u2013276 (2020).","journal-title":"Nature"},{"key":"1392_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"1392_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","volume":"31","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 31, 1212\u20131214 (2021).","journal-title":"Cell Res."},{"key":"1392_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","volume":"6","author":"JL Zhang","year":"2021","unstructured":"Zhang, J. L. et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct. Target Ther. 6, 414 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1392_CR31","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"1392_CR32","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"1392_CR33","doi-asserted-by":"publisher","first-page":"e0111721","DOI":"10.1128\/AAC.01117-21","volume":"65","author":"VC Yan","year":"2021","unstructured":"Yan, V. C. & Florian, L. M. Why remdesivir failed: preclinical assumptions overestimate the clinical efficacy of remdesivir for COVID-19 and Ebola. Antimicrob. Agents Chemother. 65, e0111721 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1392_CR34","doi-asserted-by":"publisher","first-page":"eabq7360","DOI":"10.1126\/scitranslmed.abq7360","volume":"15","author":"E Heilmann","year":"2022","unstructured":"Heilmann, E. et al. SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci. Transl. Med. 15, eabq7360 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1392_CR35","doi-asserted-by":"publisher","first-page":"103004","DOI":"10.1016\/j.jbc.2023.103004","volume":"299","author":"GD Noske","year":"2023","unstructured":"Noske, G. D. et al. Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 Main Protease naturally occurring polymorphisms. J. Biol. Chem. 299, 103004 (2023).","journal-title":"J. Biol. Chem."},{"key":"1392_CR36","doi-asserted-by":"publisher","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir resistant SARS-CoV-2 variants with high fitness in vitro. Sci Adv. 8, eadd7197 (2022).","journal-title":"Sci Adv."},{"key":"1392_CR37","doi-asserted-by":"publisher","first-page":"e0281522","DOI":"10.1128\/mbio.02815-22","volume":"14","author":"D Jochmans","year":"2023","unstructured":"Jochmans, D. et al. The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. mBio 14, e0281522 (2023).","journal-title":"mBio"},{"key":"1392_CR38","doi-asserted-by":"publisher","unstructured":"Hu, Y. et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. bioRxiv 497978 (2022); https:\/\/doi.org\/10.1101\/2022.06.28.497978.","DOI":"10.1101\/2022.06.28.497978"},{"key":"1392_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"1392_CR40","doi-asserted-by":"publisher","unstructured":"Moghadasi, S. A. et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bioRxiv 503099; https:\/\/doi.org\/10.1101\/2022.08.07.503099.","DOI":"10.1101\/2022.08.07.503099"},{"key":"1392_CR41","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1021\/acs.biochem.2c00489","volume":"61","author":"VM Sasi","year":"2022","unstructured":"Sasi, V. M. et al. Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening. Biochemistry 61, 2495\u20132505 (2022).","journal-title":"Biochemistry"},{"key":"1392_CR42","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331\u20131335 (2020).","journal-title":"Science"},{"key":"1392_CR43","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"J Qiao","year":"2021","unstructured":"Qiao, J. et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science 371, 1374\u20131378 (2021).","journal-title":"Science"},{"key":"1392_CR44","doi-asserted-by":"publisher","first-page":"eabe0751","DOI":"10.1126\/sciadv.abe0751","volume":"6","author":"MD Sacco","year":"2020","unstructured":"Sacco, M. D. et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci. Adv. 6, eabe0751 (2020).","journal-title":"Sci. Adv."},{"key":"1392_CR45","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.xcrm.2022.100743","volume":"3","author":"JF Chan","year":"2022","unstructured":"Chan, J. F. et al. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. Cell Rep. Med. 3, 100743 (2022).","journal-title":"Cell Rep. Med."},{"key":"1392_CR46","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","volume":"7","author":"BX Quan","year":"2022","unstructured":"Quan, B. X. et al. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nat. Microbiol. 7, 716\u2013725 (2022).","journal-title":"Nat. Microbiol."},{"key":"1392_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693\u2013699 (2022).","journal-title":"Nature"},{"key":"1392_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"1392_CR49","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","volume":"603","author":"R Suzuki","year":"2022","unstructured":"Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700\u2013705 (2022).","journal-title":"Nature"},{"key":"1392_CR50","unstructured":"World Health Organization (WHO), Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern (2021); https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"1392_CR51","unstructured":"World Health Organization (WHO), Update 80: What we know about new COVID-19 Variants of Concern\u2014the latest on the global situation & Omicron BA.4\/5 (2021); https:\/\/www.who.int\/publications\/m\/item\/update-80-covid-19-omicron-ba-4-5-update."},{"key":"1392_CR52","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jmv.27585","volume":"94","author":"RK Mohapatra","year":"2022","unstructured":"Mohapatra, R. K. et al. Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID-19 cases: a challenging global threat with a special focus on the Indian subcontinent. J. Med. Virol. 94, 1761\u20131765 (2022).","journal-title":"J. Med. Virol."},{"key":"1392_CR53","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","volume":"27","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat. Struct. Mol. Biol. 27, 529\u2013532 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1392_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18233-x","volume":"11","author":"L Fu","year":"2020","unstructured":"Fu, L. et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 11, 4417 (2020).","journal-title":"Nat. Commun."},{"key":"1392_CR55","doi-asserted-by":"publisher","first-page":"eabc5332","DOI":"10.1126\/scitranslmed.abc5332","volume":"12","author":"AD Rathnayake","year":"2020","unstructured":"Rathnayake, A. D. et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci. Transl. Med. 12, eabc5332 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1392_CR56","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","volume":"65","author":"SH Han","year":"2022","unstructured":"Han, S. H. et al. Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro). J. Med. Chem. 65, 2880\u20132904 (2022).","journal-title":"J. Med. Chem."},{"key":"1392_CR57","unstructured":"Pfizer Laboratories. 2022. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16474."},{"key":"1392_CR58","doi-asserted-by":"crossref","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr 66, 125\u2013132 (2010).","DOI":"10.1107\/S0907444909047337"},{"key":"1392_CR59","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. et al. How good are my data and what is the resolution? Acta Crystallogr. D. Biol. Crystallogr. 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"1392_CR60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refnement with phenix.refne. Acta Crystallogr. D. Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"1392_CR61","unstructured":"Bricogne, G. et al. BUSTER version 2.10.3. Global Phasing Ltd (2017)."},{"key":"1392_CR62","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P. et al. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"1392_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20457-w","volume":"12","author":"H Chu","year":"2021","unstructured":"Chu, H. et al. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nat. Commun. 12, 134 (2021).","journal-title":"Nat. Commun."},{"key":"1392_CR64","doi-asserted-by":"publisher","first-page":"103643","DOI":"10.1016\/j.ebiom.2021.103643","volume":"73","author":"H Shuai","year":"2021","unstructured":"Shuai, H. et al. Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine 73, 103643 (2021).","journal-title":"EBioMedicine"},{"key":"1392_CR65","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1080\/22221751.2022.2117098","volume":"11","author":"B Hu","year":"2022","unstructured":"Hu, B. et al. Spike mutations contributing to the altered entry preference of SARS-CoV-2 Omicron BA.1 and BA.2. Emerg. Microbes Infect. 11, 2275\u20132287 (2022).","journal-title":"Emerg. Microbes Infect."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01392-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01392-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01392-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T15:56:02Z","timestamp":1679846162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01392-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01392-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declared no competing interests. S.Y. is the member of editorial board, he has not been involved in the process of the manuscript handling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}